David Cruikshank is a Venture Partner at ARCH Venture Partners. He joined ARCH in 2007 and focuses on instrumentation, biotechnology, medical diagnostics & devices, semiconductors, nanotechnology, advanced materials, and information technologies. David is a Director at GenPass and has supported multiple companies including Omniome, Encodia, Nanosys, Boreal Genomics, Arbor Biotechnologies, Ultivue, Cytrellis Biosystems, Agrivida, AgBiome, 908 Devices (MASS), Twist Bioscience (TWST), Ciespace (acquired by ESI), PixelEXX Systems, and Crystal IS (acquired by Asahi Kasei).
Mr. Cruikshank was formerly with Toshiba America Electronic Components as a Business Development Manager and was responsible for North American audio, video, and automotive semiconductor product lines with annual sales of $50 million. Prior to that, he was with Conexant Systems as an Industrial Engineer.
Mr. Cruikshank holds an M.B.A. with Honors from the University of Chicago, an M.S. in Industrial Engineering and Operations Research from University of California, Berkeley, and a B.S. in Mechanical Engineering from the University of California, Los Angeles, where he graduated Summa Cum Laude and was elected to Phi Beta Kappa.